CD19 and plasma cell myeloma: Apart from four approved CD19-targeted CAR T cell therapies including lisocabtagene maraleucel (Breyanzi®), tisagenlecleucel (Kymriah®), axicabtagene ciloleucel (Yescarta®), and brexucabtagene autoleucel (Tecartus®), the first BCMA-directed CAR T cells idecabtagene vicleucel (Abecma®) was approved by the FDA for multiple myeloma on March 26, 2021 based on a 72% overall response rate and a 28% stringent complete response rate from a phase 2 KarMMa trial involving 127 patients with relapsed or refractory multiple myeloma (31).